百济神州这次亏大发了

中金在线
Apr 09

4月3日,“ 创新药 一哥”的 百济神州 宣布停止其投入近21亿元的TIGIT抗体Ociperlimab(欧司珀利单抗,BGB-A1217)肺癌临床开发计划。百济神州发布声明称,根据预设的无效性分析,该药物项目可能无法达到预期的总生存期效果。在审阅分析报告后,公司的独立监测委员会建议终止这项代号为AdvanTIG-302的三期临床试验。尽管药物的安全性没有出现新问题,但经过全面评估,百济神州还是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10